Mammary Cell News Volume 5.32 | Aug 15 2013

Mutant PIK3CA Accelerates HER2-Driven Transgenic Mammary Tumors and Induces Resistance to Combinations of Anti-HER2 Therapies
Investigators generated a mouse model of human epidermal growth factor receptor 2 (HER2)-overexpressing, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)^H1047R-mutant breast cancer. Mice expressing both human HER2 and mutant PIK3CA in the mammary epithelium developed tumors with shorter latencies compared with mice expressing either oncogene alone. [Proc Natl Acad Sci USA] Abstract

Downregulation of MicroRNA-515-5p by the Estrogen Receptor Modulates Sphingosine Kinase-1 and Breast Cancer Cell Proliferation
The authors describe that microRNA (miR)-515-5p is transcriptionally repressed by ERα and functions as a tumor suppressor in breast cancer. Its’ down-regulation enhances cell proliferation and estrogen-dependent sphingosine kinase 1 activity, mediated by a reduction of miR-515-5p post-transcriptional repression. [Cancer Res] Abstract

Loss of PPARγ Expression in Mammary Secretory Epithelial Cells Creates a Pro-Breast Tumorigenic Environment
Mammary secretory epithelial (MSE)-specific loss of peroxisome proliferator-activated receptor (PPARγ) was hypothesized to enhance 7,12-dimethylbenz[a]anthracene-mediated breast tumorigenesis. To test this, MSE cell-specific PPARγ knockout and control mice were generated, mated and allowed to nurse for three days. [Int J Cancer] Abstract | Full Article

BRCC2 Inhibits Breast Cancer Cell Growth and Metastasis In Vitro and In Vivo via Downregulating AKT Pathway
Researchers investigated the role of breast cancer cell 2 (BRCC2) in tumor suppression in breast cancer. In clinical breast cancer samples, they found that BRCC2 expression was significantly downregulated in cancer lesions compared with paired normal breast tissues. [Cell Death Dis] Full Article

Novel Sorafenib Analogues Induce Apoptosis through SHP-1 Dependent STAT3 Inactivation in Human Breast Cancer Cells
Researchers tested the efficacy of two sorafenib analogues, SC-1 and SC-43, in breast cancer cells and examined the drug mechanism. Breast cancer cell lines were used for in vitro studies. [Breast Cancer Res] Abstract | Full Article

Enhancement of Natural Killer Cell Cytotoxicity by Sodium/Iodide Symporter Gene-Mediated Radioiodine Pretreatment in Breast Cancer Cells
Scientists showed that radioiodine (I-131) therapy can modulate microenvironment of breast cancer and improve the therapeutic effect by enhancing natural killer (NK) cell cytotoxicity to the tumor cells. The susceptibility of breast cancer cells to NK cell was increased by precedent I-131 treatment in vitro. [PLoS One] Full Article

Loss of Akt1 or Akt2 Delays Mammary Tumor Onset and Suppresses Tumor Growth Rate in MTB-IGFIR Transgenic Mice
The impact of disrupting Akt1 or Akt2 in mammary tumors induced by type I insulin-like growth factor receptor (IGFIR) overexpression were examined to determine whether specific Akt isoforms regulate different aspects of mammary tumorigenesis. [BMC Cancer] Full Article

RABEX-5 Plays an Oncogenic Role in Breast Cancer by Activating Matrix Metallopeptidase 9 Pathway
Researchers aimed to investigate the role of RABEX-5 in proliferation and metastasis of breast cancer in vitro and ex vivo. [J Exp Clin Cancer Res] Abstract | Full Article

Cadmium Modifies the Cell Cycle and Apoptotic Profiles of Human Breast Cancer Cells Treated with 5-Fluorouracil
The authors studied the effects of cadmium (Cd) on cell cycle, apoptosis, and gene and protein expression in MCF-7 breast cancer cells treated with 5-Fluorouracil (5-FU). Cd altered the cell cycle profile, and its effects were greater when used either alone or in combination with 5-FU compared with 5-FU alone. [Int J Mol Sci] Abstract | Full Article

CLINICAL RESEARCH

Adjuvant Bevacizumab-Containing Therapy in Triple-Negative Breast Cancer (BEATRICE): Primary Results of a Randomized, Phase III Trial
Investigators assessed the addition of bevacizumab to chemotherapy in the adjuvant setting for women with triple-negative breast cancer. For this open-label, randomized Phase III trial they recruited patients with centrally confirmed triple-negative operable primary invasive breast cancer from 360 sites in 37 countries. [Lancet Oncol] Abstract

Ten-Year Survival in Patients with BRCA1-Negative and BRCA1-Positive Breast Cancer
To estimate 10-year overall survival rates for patients with early-onset breast cancer, with and without a BRCA1 mutation, and to identify prognostic factors among those with BRCA1-positive breast cancer. [J Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Endomagnetics in £2.1 Million Fund Raising
Endomagnetics, the company developing a portfolio of products to improve the standard of breast cancer management, has successfully closed an investment round totaling £2.1 million. The funds will be used to expand the Endomagnetics team and provide additional resource to develop the company’s business in overseas markets. [Endomagnetics] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR^TM can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Postdoctoral Fellow – Mammary Stem Cell (North Carolina Central University)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Postdoctoral Fellow – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Breast Cancer Cell Research (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Fellow – Breast and Renal Cell Carcinoma Research (University of North Carolina – Chapel Hill)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.